

- 3 de Gracia J, Vendrell M, Álvarez A, *et al.* Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. *Int Immunopharmacol* 2004; 6: 745–753.
- 4 de Gracia J, Morell F, Bofill JM, Rodrigo MJ, Coscolluela C. Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3. *N Engl J Med* 1986; 314: 925–926.
- 5 de Gracia J, Miravittles M, Vendrell M, Rodrigo MJ, Codina R, Morell F. Study of the IgG subclasses in symptomatic patients with IgA deficiency. *Med Clin (Barc)* 1995; 104: 728–731.
- 6 Rodrigo MJ, Vendrell M, Cruz MJ, *et al.* Utility of the antibody response to a conjugated *H. influenzae* type B vaccine for diagnosis of primary humoral immunodeficiency. *Am J Respir Crit Care Med* 2000; 162: 1462–1465.
- 7 Rodrigo MJ, Miravittles M, Cruz MJ, *et al.* Characterization of specific immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23-valent pneumococcal vaccine in a healthy adult population: proposal for response criteria. *Clin Diagn Lab Immunol* 1997; 4: 168–172.
- 8 Vendrell M, de Gracia J, Rodrigo MJ, *et al.* Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. *Chest* 2005; 127: 197–204.
- 9 Ambrosino DM, Siber GR, Chilmoneczyk BA, Jernberg JB, Finberg RW. An immunodeficiency characterized by impaired antibody responses to polysaccharides. *N Engl J Med* 1987; 316: 790–793.
- 10 de Gracia J, Rodrigo MJ, Morell F, *et al.* IgG subclass deficiencies associated with bronchiectasis. *Am J Respir Crit Care Med* 1996; 153: 650–655.
- 11 Miravittles M, de Gracia J, Rodrigo MJ, *et al.* Specific antibody response against the 23-valent pneumococcal vaccine in patients with α_1 -antitrypsin deficiency with and without bronchiectasis. *Chest* 1999; 116: 946–952.

DOI: 10.1183/09031936.05.00027605

Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension

To the Editors:

HOEPER *et al.* [1] have produced an interesting report of their clinical experience of combined therapy with bosentan and sildenafil in patients with idiopathic pulmonary arterial hypertension. Whilst it is true that the relatively scant literature supporting the use of phosphodiesterase-5 inhibitors is centred around sildenafil, its relatively short duration of action requires the use of a thrice-daily regime. This has significant implications for compliance and, since treatment is continual, has large implications in the cost of treatment. It would be more logical to use a long-acting phosphodiesterase-5 inhibitor, and, with the advent of tadalafil, once-daily treatment becomes possible.

Here, we report our experience with a combination of bosentan and tadalafil in a 42-yr-old male with idiopathic pulmonary hypertension who had documented poor compliance with nebulised iloprost. Sildenafil 25 mg *t.d.s.* was added to bosentan, following a clinical deterioration and the finding of an estimated pulmonary artery systolic pressure of 130 mmHg, and this caused a fall in pulmonary artery pressure to 50 mmHg. Treatment with sildenafil was stopped 1 month later at another centre, and the pulmonary artery systolic pressure increased to 100 mmHg. Subsequently, sildenafil was restarted in combination with bosentan, and exercise tolerance doubled. After 3 months of combination treatment, the issue of compliance was raised by the patient and it was decided to

substitute tadalafil 20 mg once daily for the sildenafil. The patient has continued on tadalafil for 9 months with an excellent symptomatic response. The last estimated pulmonary artery pressure was 61 mmHg.

A.H. Morice, S. Mulrennan and A. Clark

Division of Academic Medicine, University of Hull, Castle Hill Hospital, Hull, UK.

REFERENCE

- 1 Hoepfer MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. *Eur Respir J* 2004; 24: 1007–1010.

DOI: 10.1183/09031936.05.00030405

From the authors:

I am grateful for the comments by A.H. Morice and coworkers, although their case report leaves several questions unanswered. More information than just the systolic pulmonary artery pressure is needed to appraise the haemodynamic response to tadalafil. One wonders whether this patient ever underwent pulmonary vasoreactivity testing. With such a

Login

 0 items

 **ERS | PUBLICATIONS**

Search within ERS publications

Correspondence  Free

Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension

A. H. Morice | S. Mulrennan | A. Clark

European Respiratory Journal 2005 26(1): 180-180; DOI:
<https://doi.org/10.1183/09031936.05.00030405>

 PDF  Permissions  Add to Favourites
 Labels  Cite  Share  Alerts



This article appears in:
European Respiratory
Journal
Vol 26 Issue 1

 Focus < Previous Next >

Article

Info & Metrics

Article Information

vol. 26 no. 1 Page: 180-180

DOI <https://doi.org/10.1183/09031936.05.00030405>

Print ISSN [0903-1936](#)

Online ISSN [1399-3003](#)

History Published online 1 July 2005

Copyright & Usage © ERS Journals Ltd